Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + ricolinostat
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of nab-paclitaxel and ricolinostat (ACY-1215) has been studied in clinical trials for metastatic breast cancer. This combination therapy has shown promising results, particularly in hormone receptor-positive/HER2-negative breast cancer patients. Nab-paclitaxel is an albumin-bound formulation of paclitaxel, a taxane chemotherapy agent. Ricolinostat is a selective histone deacetylase 6 (HDAC6) inhibitor that has shown potential anticancer activity. The combination was investigated in a phase 1b clinical trial (NCT02632071) to determine the maximum tolerated dose (MTD) and evaluate its safety and tolerability.
02
Targets
HDAC6 (Histone deacetylase 6)TUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on nab-paclitaxel + ricolinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + ricolinostat.